Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-10-16 12:25:20 UTC |
---|
Update Date | 2022-03-07 02:49:25 UTC |
---|
HMDB ID | HMDB0005006 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Atorvastatin |
---|
Description | Atorvastatin is a member of the drug class known as statins, used for lowering cholesterol and thereby reducing cardiovascular disease. Atorvastatin inhibits a rate-determining enzyme located in hepatic tissue used in cholesterol synthesis, which lowers the amount of cholesterol produced. This also has the effect of lowering the total amount of LDL cholesterol; Atorvastatin is a member of the drug class known as statins, used for lowering cholesterol and thereby reducing cardiovascular disease. Atorvastatin inhibits a rate-determining enzyme located in hepatic tissue used in cholesterol synthesis, which lowers the amount of cholesterol produced. This also has the effect of lowering the total amount of LDL cholesterol; As with other statins, atorvastatin is a competitive inhibitor of HMG-CoA reductase. Unlike most others, however, it is a completely synthetic compound. HMG-CoA reductase catalyzes the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, which is the rate-limiting step in hepatic cholesterol biosynthesis. Inhibition of the enzyme decreases de novo cholesterol synthesis, increasing expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes. This increases the LDL uptake by the hepatocytes, decreasing the amount of LDL in the blood. |
---|
Structure | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1 InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 |
---|
Synonyms | Value | Source |
---|
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid | ChEBI | 7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID | ChEBI | Atorlip | ChEBI | Atorpic | ChEBI | Atorvastatina | ChEBI | Atorvastatine | ChEBI | Atorvastatinum | ChEBI | Liprimar | ChEBI | Lipitor | Kegg | Sortis | Kegg | (R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate | Generator | (R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid | Generator | (R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate | Generator | (R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate | Generator | (R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid | Generator | 7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate | Generator | (R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate | HMDB | (R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid | HMDB | Atorvastatin acid | HMDB | Atorvastatin calcium | HMDB | Cardyl | HMDB | Anhydrous, atorvastatin calcium | HMDB | Calcium hydrate, atorvastatin | HMDB | Calcium trihydrate, atorvastatin | HMDB | Calcium, atorvastatin | HMDB | Hydrate, atorvastatin calcium | HMDB | Atorvastatin calcium trihydrate | HMDB | Atorvastatin, calcium salt | HMDB | Liptonorm | HMDB | Trihydrate, atorvastatin calcium | HMDB | Atorvastatin calcium anhydrous | HMDB | Calcium anhydrous, atorvastatin | HMDB | Calcium salt atorvastatin | HMDB | Atorvastatin calcium hydrate | HMDB | (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid | MeSH |
|
---|
Chemical Formula | C33H35FN2O5 |
---|
Average Molecular Weight | 558.6398 |
---|
Monoisotopic Molecular Weight | 558.253000445 |
---|
IUPAC Name | (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid |
---|
Traditional Name | atorvastatin |
---|
CAS Registry Number | 134523-00-5 |
---|
SMILES | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1 |
---|
InChI Identifier | InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 |
---|
InChI Key | XUKUURHRXDUEBC-KAYWLYCHSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as diphenylpyrroles. These are aromatic heterocyclic compounds with a structure based on a pyrrole ring linked to exactly two phenyl groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyrroles |
---|
Sub Class | Substituted pyrroles |
---|
Direct Parent | Diphenylpyrroles |
---|
Alternative Parents | |
---|
Substituents | - 2,3-diphenylpyrrole
- Aromatic anilide
- Medium-chain hydroxy acid
- Pyrrole-3-carboxamide
- Pyrrole-3-carboxylic acid or derivatives
- Medium-chain fatty acid
- Beta-hydroxy acid
- Fluorobenzene
- Halobenzene
- Halogenated fatty acid
- Heterocyclic fatty acid
- Hydroxy fatty acid
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Hydroxy acid
- Fatty acyl
- Fatty acid
- Benzenoid
- Vinylogous amide
- Heteroaromatic compound
- Secondary carboxylic acid amide
- Secondary alcohol
- Carboxamide group
- Monocarboxylic acid or derivatives
- Azacycle
- Carboxylic acid derivative
- Carboxylic acid
- Carbonyl group
- Organopnictogen compound
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organonitrogen compound
- Organooxygen compound
- Organic nitrogen compound
- Alcohol
- Organohalogen compound
- Organofluoride
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 159.1 - 190.6 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Atorvastatin,1TMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C | 4320.6 | Semi standard non polar | 33892256 | Atorvastatin,1TMS,isomer #2 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C | 4322.9 | Semi standard non polar | 33892256 | Atorvastatin,1TMS,isomer #3 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C | 4271.6 | Semi standard non polar | 33892256 | Atorvastatin,1TMS,isomer #4 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O | 4158.4 | Semi standard non polar | 33892256 | Atorvastatin,2TMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C | 4305.7 | Semi standard non polar | 33892256 | Atorvastatin,2TMS,isomer #2 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 4265.5 | Semi standard non polar | 33892256 | Atorvastatin,2TMS,isomer #3 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C | 4138.0 | Semi standard non polar | 33892256 | Atorvastatin,2TMS,isomer #4 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 4269.1 | Semi standard non polar | 33892256 | Atorvastatin,2TMS,isomer #5 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C | 4157.7 | Semi standard non polar | 33892256 | Atorvastatin,2TMS,isomer #6 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C | 4113.0 | Semi standard non polar | 33892256 | Atorvastatin,3TMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 4278.8 | Semi standard non polar | 33892256 | Atorvastatin,3TMS,isomer #2 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C | 4158.7 | Semi standard non polar | 33892256 | Atorvastatin,3TMS,isomer #3 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 4118.1 | Semi standard non polar | 33892256 | Atorvastatin,3TMS,isomer #4 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 4127.9 | Semi standard non polar | 33892256 | Atorvastatin,4TMS,isomer #1 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 4143.2 | Semi standard non polar | 33892256 | Atorvastatin,4TMS,isomer #1 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 3386.1 | Standard non polar | 33892256 | Atorvastatin,4TMS,isomer #1 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 4792.1 | Standard polar | 33892256 | Atorvastatin,1TBDMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C(C)(C)C | 4509.1 | Semi standard non polar | 33892256 | Atorvastatin,1TBDMS,isomer #2 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C | 4501.3 | Semi standard non polar | 33892256 | Atorvastatin,1TBDMS,isomer #3 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C | 4487.3 | Semi standard non polar | 33892256 | Atorvastatin,1TBDMS,isomer #4 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O | 4359.5 | Semi standard non polar | 33892256 | Atorvastatin,2TBDMS,isomer #1 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4647.0 | Semi standard non polar | 33892256 | Atorvastatin,2TBDMS,isomer #2 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4632.1 | Semi standard non polar | 33892256 | Atorvastatin,2TBDMS,isomer #3 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C(C)(C)C | 4494.1 | Semi standard non polar | 33892256 | Atorvastatin,2TBDMS,isomer #4 | CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4622.1 | Semi standard non polar | 33892256 | Atorvastatin,2TBDMS,isomer #5 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C | 4511.9 | Semi standard non polar | 33892256 | Atorvastatin,2TBDMS,isomer #6 | CC(C)C1=C(C(=O)N(C2=CC=CC=C2)[Si](C)(C)C(C)(C)C)C(C2=CC=CC=C2)=C(C2=CC=C(F)C=C2)N1CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C | 4481.4 | Semi standard non polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (Non-derivatized) - 70eV, Positive | splash10-000f-5100950000-b76d194b9679e4b35417 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (1 TMS) - 70eV, Positive | splash10-082i-5320938000-c1984e6bf123460d28ac | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS ("Atorvastatin,1TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_3_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TMS_3_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_1_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_4) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Atorvastatin GC-MS (TBDMS_2_5) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-0a4i-0000090000-ae5c999b091a2bc93933 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-0a4i-0000190000-dd563e18b1f0f74aadd5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-0zfs-0007960000-cb66a18d2f0a687261ba | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-002b-0059000000-0942bc1e35434cd7d0d3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-QTOF , negative-QTOF | splash10-004i-0093000000-f42ba46820a3cf3295c5 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0udj-0005910000-b09ba5f3b86948c7f3cb | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0000090000-6f297ca79ae1761aac33 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0002-1009300000-9479520f395dcdd585e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-004i-0092000000-9b561b8d35c3bdc5e46a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-004i-0090000000-3aad87273e7f9942a50f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-01t9-1090000000-3f0efff41ebdb5320ce4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-03di-2090000000-0227638704b90c4249d0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0000090000-65c729c6734f6533c431 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0002-1009300000-9122e4479d8c0c32bb0d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-004i-0092000000-22d639a8882509e1bcdb | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-004i-0090000000-30a0198165bae85fa258 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-01t9-1090000000-cb3feea45f5280f05c37 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-03di-2090000000-8db2f70b373277f143c0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atorvastatin LC-ESI-ITFT , negative-QTOF | splash10-0udj-0005910000-a63c845ca248d958068d | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 10V, Positive-QTOF | splash10-006x-1000190000-5418613834968283e5a8 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 20V, Positive-QTOF | splash10-006y-3101940000-2906ea9feb05e2fc0cfc | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 40V, Positive-QTOF | splash10-006x-8438900000-f5abfdde8ad50c98b16e | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 10V, Negative-QTOF | splash10-0a4i-1000290000-949ba837ddf712ee8558 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 20V, Negative-QTOF | splash10-0a4s-6203960000-9adcd151fdfe389c7d00 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atorvastatin 40V, Negative-QTOF | splash10-054o-9158000000-7b64ce4c34d6e9fae2b8 | 2017-07-26 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Membrane (predicted from logP)
|
---|
Biospecimen Locations | |
---|
Tissue Locations | |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.010 +/- 0.0044 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.22 +/- 0.16 uM | Adult (>18 years old) | Both | Sepsis | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Sepsis |
---|
- Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M: A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med. 2009 Apr;35(4):717-21. doi: 10.1007/s00134-008-1358-3. Epub 2008 Nov 26. [PubMed:19034423 ]
| Colorectal cancer |
---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
|
|
---|
Associated OMIM IDs | |
---|
External Links |
---|
DrugBank ID | DB01076 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB023579 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 54810 |
---|
KEGG Compound ID | C06834 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Atorvastatin |
---|
METLIN ID | 1136 |
---|
PubChem Compound | 60823 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 39548 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | MDB00000466 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Roth, Bruce David. Preparation of anticholesteremic (R-(R*R*))-2-(4-fluorophenyl)-b, d-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)carbonyl)-1H-pyrrolyl-1-heptanoic acid, its lactone form and salts thereof. Eur. Pat. Appl. (1991), 18 pp. CODEN: EPXXDW EP 409281 A1 19910123 CAN 115:29107 AN 1991:429107 |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI: Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother. 2004 Feb;38(2):205-8. Epub 2003 Dec 19. [PubMed:14742751 ]
- Funatsu T, Suzuki K, Goto M, Arai Y, Kakuta H, Tanaka H, Yasuda S, Ida M, Nishijima S, Miyata K: Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis. 2001 Jul;157(1):107-15. [PubMed:11427209 ]
- Tannous M, Cheung R, Vignini A, Mutus B: Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost. 1999 Nov;82(5):1390-4. [PubMed:10595624 ]
- Naoumova RP, Dunn S, Rallidis L, Abu-Muhana O, Neuwirth C, Rendell NB, Taylor GW, Thompson GR: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res. 1997 Jul;38(7):1496-500. [PubMed:9254075 ]
- Izar MC: [Hypolipidemic treatment under special conditions: posttransplant and/or immunosuppressive therapy]. Arq Bras Cardiol. 2005 Oct;85 Suppl 5:50-7. Epub 2006 Jan 2. [PubMed:16400400 ]
- Hwang YS, Tsai WC, Lu YH, Lin CC, Chen YF: Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia. Am J Cardiol. 2004 Aug 1;94(3):364-6. [PubMed:15276107 ]
- Bruni F, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Sawamura T, Gioffre WR, Auteri A, Puccetti L: Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects. Clin Appl Thromb Hemost. 2005 Oct;11(4):417-28. [PubMed:16244767 ]
- Fenton JW 2nd, Brezniak DV, Ofosu FA, Shen GX, Jacobson JR, Garcia JG: Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Apr;5(2):115-20. [PubMed:15853752 ]
- Pokrovskaia EV, Vaulin NA, Gratsianskii NA, Averkov OV, Deev AD: [Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin]. Kardiologiia. 2003;43(1):7-18. [PubMed:12891281 ]
- Funatsu T, Kakuta H, Tanaka H, Arai Y, Suzuki K, Miyata K: [Atorvastatin (Lipitor): a review of its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi. 2001 Jan;117(1):65-76. [PubMed:11233299 ]
- Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C: Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol. 2006 Jan 26;106(3):333-7. [PubMed:16337041 ]
- Malinowski JM: Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm. 1998 Nov 1;55(21):2253-67; quiz 2302-3. [PubMed:9825877 ]
|
---|